ATP Analog Combination Therapy With Adenosine Receptor Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional cancer treatments using ATP analogs, such as tyrosine kinase inhibitors, often result in side effects like diarrhea and hand-foot syndrome, and combining these with nucleoside or nucleobase analogs leads to problematic side effects and dose reductions due to off-target effects, with the mechanisms poorly understood.
Innovation Solution
Administering an adenosine receptor antagonist, such as methylxanthines like caffeine or theophylline, alongside or before ATP analogs to mitigate side effects and enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ATP analogs (tyrosine kinase inhibitors) are administered to treat cancer, then cancer treatment efficacy is improved, but side effects such as diarrhea and hand-foot syndrome occur
Solution Approach 1:
The patent introduces adenosine receptor antagonists as intermediary substances that mediate between the ATP analog treatment and the adenosine receptors responsible for side effects. The antagonist blocks the harmful interaction between accumulated adenosine and its receptors, thereby preventing side effects while allowing the ATP analog to continue its anticancer action through its primary mechanism
Solution Approach 2:
The patent extracts and addresses the specific harmful mechanism (adenosine receptor activation) separate from the therapeutic mechanism (tyrosine kinase inhibition). By targeting only the adenosine receptor pathway with a selective antagonist, the treatment removes the harmful effects while preserving the beneficial anticancer activity of the ATP analog
2Reliability
If ATP analogs are combined with nucleoside or nucleobase analogs for improved cancer treatment, then treatment efficacy is enhanced, but problematic side effects occur and dose reductions are required
Solution Approach 1:
The adenosine receptor antagonist serves as a protective intermediary that shields the patient from the harmful interactions that occur when ATP analogs and nucleoside/nucleobase analogs are combined. This allows both anticancer agents to be administered at full therapeutic doses without the problematic side effects that would otherwise force dose reductions
3Object-affected harmful factors
If the dose of ATP analogs is reduced to manage side effects, then side effect severity is decreased, but treatment efficacy is compromised
Solution Approach 1:
The patent separates the side effect management function from the dose adjustment approach. Instead of reducing the ATP analog dose to manage side effects, the invention extracts and treats the side effect mechanism independently using adenosine receptor antagonists, thereby maintaining full therapeutic dosing while controlling side effects
Data Source
AI summary
A method for treating an ATP analog-induced side effect in a subject comprises administering an effective amount of an adenosine receptor antagonist to the subject. A method for treating cancer in a subject comprises administering a nucleobase and/or nucleoside prior to administering an ATP analog.